Copyright
©The Author(s) 2025.
World J Clin Oncol. Feb 24, 2025; 16(2): 98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Table 3 Adverse events occurring in the two groups, n
| Combination group, grade 1 | Combination group, grade 2 | Combination group, grade 3 | Combination group, grade 4 | Chemotherapy group, grade 1 | Chemotherapy group, grade 2 | Chemotherapy group, grade 3 | Chemotherapy group, grade 4 | |
| Leukopenia | 14 | 10 | 5 | 1 | 12 | 9 | 3 | 1 |
| Fatigue | 15 | 9 | 2 | 0 | 17 | 8 | 2 | 0 |
| Anemia | 16 | 6 | 1 | 0 | 14 | 7 | 1 | 0 |
| Nausea | 22 | 11 | 1 | 0 | 21 | 12 | 1 | 0 |
| Anorexia | 13 | 8 | 0 | 0 | 12 | 9 | 0 | 0 |
- Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. World J Clin Oncol 2025; 16(2): 98079
- URL: https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i2.98079